Literature DB >> 31772296

Revisiting complete response in light chain amyloidosis.

Surbhi Sidana1,2, Angela Dispenzieri2, David L Murray3, Ronald S Go2, Francis K Buadi2, Martha Q Lacy2, Wilson I Gonsalves2, David Dingli2, Rahma Warsame2, Taxiarchis Kourelis2, Eli Muchtar2, Suzanne R Hayman2, Prashant Kapoor2, Robert A Kyle2, Nelson Leung2,4, S Vincent Rajkumar2, Morie A Gertz2, Shaji K Kumar5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31772296      PMCID： PMC8083944          DOI： 10.1038/s41375-019-0664-9

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

1.  Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.

Authors:  Amandeep Godara; Denis Toskic; Jack Albanese; Benjamin Rosenthal; Nauman S Siddiqui; Adin Kugelmass; Ping Zhou; Teresa Fogaren; Cindy Varga; Heather J Landau; Raymond L Comenzo
Journal:  Am J Hematol       Date:  2020-11-05       Impact factor: 10.047

2.  Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.

Authors:  Giovanni Palladini; Bruno Paiva; Ashutosh Wechalekar; Margherita Massa; Paolo Milani; Marta Lasa; Sriram Ravichandran; Isabel Krsnik; Marco Basset; Leire Burgos; Mario Nuvolone; Ramón Lecumberri; Andrea Foli; Noemi Puig; Melania Antonietta Sesta; Margherita Bozzola; Pasquale Cascino; Alice Nevone; Jessica Ripepi; Pierpaolo Berti; Simona Casarini; Ombretta Annibali; Alberto Orfao; Jesus San-Miguel; Giampaolo Merlini
Journal:  Blood Cancer J       Date:  2021-02-16       Impact factor: 11.037

3.  Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Authors:  Gareth J Morgan; Joel N Buxbaum; Jeffery W Kelly
Journal:  Hemato       Date:  2021-10-05

4.  Detection of minimal residual disease by next generation sequencing in AL amyloidosis.

Authors:  Shayna Sarosiek; Cindy Varga; Allison Jacob; Maria Teresa Fulciniti; Nikhil Munshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-06-21       Impact factor: 11.037

5.  Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.

Authors:  Shayna Sarosiek; Luke Zheng; J Mark Sloan; Karen Quillen; Dina Brauneis; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037

6.  Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.

Authors:  Paolo Milani; Marco Basset; Mario Nuvolone; Francesca Benigna; Lara Rodigari; Francesca Lavatelli; Andrea Foli; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.